Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants After Stent Implantation
| Autor: | Raviteja R. Guddeti, Ogheneochuko Ajari, Shankar Kumar, Hardik Patel, Aditya Govindavarjhulla, Sapan Patel, Marcelo Rodrigues Zacarkim, Kristin Feeney, Daniel Nethala, Joseph R. Dunford, Prashanth Saddala, Gonzalo Romero Gonzalez, Divya Yadav, C. Michael Gibson, Madeleine Cochet, Rim Halaby, Emily Larkin, Vishnu Vardhan Serla, Farman Khan, Daniel Swarbrick, Vijay Kunadian |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Acute coronary syndrome
medicine.medical_specialty medicine.drug_class business.industry medicine.medical_treatment Anticoagulant Percutaneous coronary intervention Atrial fibrillation medicine.disease Clinical trial Internal medicine medicine Cardiology Stent implantation cardiovascular diseases Cardiology and Cardiovascular Medicine Intensive care medicine business Stroke Oral anticoagulation |
| Zdroj: | Interventional Cardiology Clinics. 2:595-606 |
| ISSN: | 2211-7458 |
| DOI: | 10.1016/j.iccl.2013.05.007 |
| Popis: | Triple oral anticoagulation or triple antiplatelet therapies may be administered for various reasons. They reduce cardiac complications following percutaneous coronary intervention and stroke or other thromboembolic phenomenon in conditions such as atrial fibrillation. There is an elevated risk of severe bleeding, so it is necessary to balance risk and benefits. Newer oral anticoagulants and antiplatelet drugs may be considered; the number of options is increasing. This article examines triple therapies and the efficacy and safety of combinations of traditional anticoagulant and antiplatelet drugs, and reviews clinical trial data on novel agents. Guidelines to inform clinical decision-making are presented. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|